Search clinical trials for: CHF5259

Total 3 results

Chiesi Farmaceutici S.p.A.
Quintiles, Inc.

Completed

Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

Copd

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD (GlycoNEXT)

Chronic Obstructive Pulmonary Disease (COPD)

Czechia, Germany, Hungary, Romania
Chiesi Farmaceutici S.p.A.

Completed

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States

3

Subscribe